This topline look at the KDIGO 2022 updated guideline highlights new recommendations for clinical use of SGLT2i, GLP-1 RA, and nonsteroidal MRA.
Find a compact sampling of 2022 chronic kidney disease research reviewed on Patient Care, chosen by the editorial staff.
Peer mentor programs can provide support for patients, especially when it comes to family planning and parenthood.
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.
CMHC. PCPs and cardiologists appeared to perform only half of items considered necessary for care of T2D patients in a new simulated patient study.
Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.
Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.
Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.
The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.